Uniqure NV

QURE · NASDAQ

$22.72+$0.515 (+2.32%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $22.20

About QURE

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company employs 221 full-time employees The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Employees: 221
Headquarters: Amsterdam, Noord-Holland
Listed: Feb 5, 2014
Sector: Health Care
Industry: Biotechnology
Website: uniqure.com

Leadership

Uniqure NV executives
Name	Title	Since	Age
David Meek	—	—	62
Matthew Kapusta	—	2015	52
Christian Klemt	—	—	52
Jeannette Potts	—	—	63
Walid Abi-Saab	—	—	59
Kylie Okeefe	—	—	—
Robert Gut	—	2018	60
Madhavan Balachandran	—	—	74
Rachelle Jacques	—	—	53
Jack Kaye	—	—	81
Leonard Post	—	—	72
Jeremy Springhorn	—	—	62
Chiara Russo	—	2025	—

Revenue by product and region

Fiscal year ended Dec 31, 2021: $524.00M total revenue

By product

License revenues$517.40M9874.0%
Represents information pertaining to collaborative revenue.$6.60M126.0%
Collaborative Revenue Including Revenue From Related Party.$4.20M80.2%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Uniqure NV suppliers and customers
Company	Relationship	Country	Correlation
4D Molecular Therapeutics FDMT	Supplier and customer	US	0.91
CSL CSL.AX	Supplier and customer	AU	0.82
REGENXBIO RGNX	Supplier and customer	US	0.82
Bristol-Myers Squibb BMY	Supplier and customer	US	-0.64
Sanofi SAN.PA	Supplier and customer	FR	-0.78
France	Supplier and customer	FR	—
Cold Spring Harbor Laboratory, Inc.	Supplier and customer	US	—
Gen X Cos.	Supplier	CA	—
St. Jude Children's Research Hospital, Inc.	Supplier and customer	US	—
United States	Supplier and customer	US	—

Similar companies

Companies in the same industry as Uniqure NV

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.